Targeting the AMPK pathway for the treatment of type 2 diabetes

Frontiers in Bioscience

Volumn 14, Issue 9, 2009, Pages 3380-3400

  Viollet, Benoit ^a,b   Lantier, Louise ^a,b   Devin Leclerc, Jocelyne ^a,b   Hebrard, Sophie ^a,b   Amouyal, Chloe ^c   Mounier, Remi ^a,b   Foretz, Marc ^a,b   Andreelli, Fabrizio ^a,b,c  

^a INSTITUT COCHIN   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

Author keywords

AMPK; Energy metabolism; Review; Type 2 diabetes

Indexed keywords

RODENTIA;

GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE;

CALORIC RESTRICTION; CARDIOVASCULAR DISEASE; CHEMISTRY; ENZYME ACTIVATION; ENZYMOLOGY; EXERCISE; HOMEOSTASIS; HUMAN; LIPID METABOLISM; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PATHOPHYSIOLOGY; PROTEIN CONFORMATION; REVIEW;

AMP-ACTIVATED PROTEIN KINASES; CALORIC RESTRICTION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; EXERCISE; GLUCOSE; HOMEOSTASIS; HUMANS; ISLETS OF LANGERHANS; LIPID METABOLISM; PROTEIN CONFORMATION;

EID: 63849085094     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/3460     Document Type: Article

References (176)

1. R. R. Wing, M. G. Goldstein, K. J. Acton, L. L. Birch, J. M. Jakicic, J. F. Sallis, Jr., D. Smith-West, R. W. Jeffery and R. S. Surwit: Behavioral science research in diabetes: lifestyle changes related to obesity, eating behavior, and physical activity. Diabetes Care, 24(1), 117-23(2001) (Pubitemid 32104231)
2. A. R. Saltiel and C. R. Kahn: Insulin signalling and the regulation of glucose and lipid metabolism. Nature, 414(6865), 799-806(2001) (Pubitemid 34000783)
3. X. R. Pan, G. W. Li, Y. H. Hu, J. X. Wang, W. Y. Yang, Z. X. An, Z. X. Hu, J. Lin, J. Z. Xiao, H. B. Cao, P. A. Liu, X. G. Jiang, Y. Y. Jiang, J. P. Wang, H. Zheng, H. Zhang, P. H. Bennett and B. V. Howard: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care, 20(4), 537-44(1997) (Pubitemid 27143412)
4. J. Tuomilehto, J. Lindstrom, J. G. Eriksson, T. T. Valle, H. Hamalainen, P. Ilanne-Parikka, S. Keinanen-Kiukaanniemi, M. Laakso, A. Louheranta, M. Rastas, V. Salminen and M. Uusitupa: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med, 344(18), 1343-50(2001) (Pubitemid 32378388)
5. W. C. Knowler, E. Barrett-Connor, S. E. Fowler, R. F. Hamman, J. M. Lachin, E. A. Walker and D. M. Nathan: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med, 346(6), 393-403(2002) (Pubitemid 34437694)
6. C. Hayes and A. Kriska: Role of physical activity in diabetes management and prevention. J Am Diet Assoc, 108(4 Suppl 1), S19-23(2008) (Pubitemid 351389295)
7. R. J. Sigal, G. P. Kenny, D. H. Wasserman and C. Castaneda-Sceppa: Physical activity/exercise and type 2 diabetes. Diabetes Care, 27(10), 2518-39(2004) (Pubitemid 39281418)
8. S. M. Grundy, A. Garber, R. Goldberg, S. Havas, R. Holman, C. Lamendola, W. J. Howard, P. Savage, J. Sowers and G. L. Vega: Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group IV: lifestyle and medical management of risk factors. Circulation, 105(18), e-1538(2002)
9. J. B. Buse, H. N. Ginsberg, G. L. Bakris, N. G. Clark, F. Costa, R. Eckel, V. Fonseca, H. C. Gerstein, S. Grundy, R. W. Nesto, M. P. Pignone, J. Plutzky, D. Porte, R. Redberg, K. F. Stitzel and N. J. Stone: Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care, 30(1), 162-72(2007) (Pubitemid 46052519)
10. N. B. Ruderman, H. Park, V. K. Kaushik, D. Dean, S. Constant, M. Prentki and A. K. Saha: AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol Scand, 178(4), 435-42(2003) (Pubitemid 36960435)
11. K. R. Segal, A. Edano, A. Abalos, J. Albu, L. Blando, M. B. Tomas and F. X. Pi-Sunyer: Effect of exercise training on insulin sensitivity and glucose metabolism in lean, obese, and diabetic men. J Appl Physiol, 71(6), 2402-11(1991)
12. N. Musi, N. Fujii, M. F. Hirshman, I. Ekberg, S. Froberg, O. Ljungqvist, A. Thorell and L. J. Goodyear: AMP-activated protein kinase (AMPK) is activated in muscle of subjects with type 2 diabetes during exercise. Diabetes, 50(5), 921-7(2001) (Pubitemid 32374520)
13. J. A. Hawley and S. J. Lessard: Exercise training-induced improvements in insulin action. Acta Physiol (Oxf), 192(1), 127-35(2008) (Pubitemid 350265363)
14. I. W. Campbell: Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract, 58(2), 192-200(2004) (Pubitemid 38425750)
15. S. A. Smith, L. E. Porter, N. Biswas and M. I. Freed: Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. J Clin Endocrinol Metab, 89(12), 6048-53(2004) (Pubitemid 39628413)
16. T. A. Buchanan, A. H. Xiang, R. K. Peters, S. L. Kjos, A. Marroquin, J. Goico, C. Ochoa, S. Tan, K. Berkowitz, H. N. Hodis and S. P. Azen: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes, 51(9), 2796-803(2002) (Pubitemid 34970933)
17. A. H. Xiang, R. K. Peters, S. L. Kjos, A. Marroquin, J. Goico, C. Ochoa, M. Kawakubo and T. A. Buchanan: Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes, 55(2), 517-22(2006) (Pubitemid 43343284)
18. H. C. Gerstein, S. Yusuf, J. Bosch, J. Pogue, P. Sheridan, N. Dinccag, M. Hanefeld, B. Hoogwerf, M. Laakso, V. Mohan, J. Shaw, B. Zinman and R. R. Holman: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 368(9541), 1096-105(2006)
19. A. R. Nawrocki, M. W. Rajala, E. Tomas, U. B. Pajvani, A. K. Saha, M. E. Trumbauer, Z. Pang, A. S. Chen, N. B. Ruderman, H. Chen, L. Rossetti and P. E. Scherer: Mice lacking adiponectin show decreased hepatic insulin sensitivity and reduced responsiveness to peroxisome proliferatoractivated receptor gamma agonists. J Biol Chem, 281(5), 2654-60(2006) (Pubitemid 43845727)
20. N. Maeda, M. Takahashi, T. Funahashi, S. Kihara, H. Nishizawa, K. Kishida, H. Nagaretani, M. Matsuda, R. Komuro, N. Ouchi, H. Kuriyama, K. Hotta, T. Nakamura, I. Shimomura and Y. Matsuzawa: PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes, 50(9), 2094-9(2001) (Pubitemid 33643677)
21. R. G. Dluhy and G. T. McMahon: Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med, 358(24), 2630-3(2008) (Pubitemid 351831365)
22. P. J. Grant: Beneficial effects of metformin on haemostasis and vascular function in man. Diabetes Metab, 29(4 Pt 2), 6S44-52(2003) (Pubitemid 37187090)
23. B. J. Davis, Z. Xie, B. Viollet and M. H. Zou: Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase. Diabetes, 55(2), 496-505(2006) (Pubitemid 43343281)
24. T. Inoue, N. Kotooka, T. Morooka, H. Komoda, T. Uchida, Y. Aso, T. Inukai, T. Okuno and K. Node: High molecular weight adiponectin as a predictor of long-term clinical outcome in patients with coronary artery disease. Am J Cardiol, 100(4), 569-74(2007) (Pubitemid 47223129)
25. A. T. Gonon, U. Widegren, A. Bulhak, F. Salehzadeh, J. Persson, P. O. Sjoquist and J. Pernow: Adiponectin protects against myocardial ischaemia-reperfusion injury via AMP-activated protein kinase, Akt, and nitric oxide. Cardiovasc Res, 78(1), 116-22(2008) (Pubitemid 351430967)
26. M. Naruszewicz, I. Laniewska, B. Millo and M. Dluzniewski: Combination therapy of statin with flavonoids rich extract from chokeberry fruits enhanced reduction in cardiovascular risk markers in patients after myocardial infraction (MI). Atherosclerosis, 194(2), e-17984(2007)
27. J. B. Birk and J. F. Wojtaszewski: Predominant alpha2/beta2/gamma3 AMPK activation during exercise in human skeletal muscle. J Physiol, 577(Pt 3), 1021-32(2006) (Pubitemid 44873663)
28. J. T. Treebak, J. B. Birk, A. J. Rose, B. Kiens, E. A. Richter and J. F. Wojtaszewski: AS160 phosphorylation is associated with activation of alpha2beta2gamma1-but not alpha2beta2gamma3-AMPK trimeric complex in skeletal muscle during exercise in humans. Am J Physiol Endocrinol Metab, 292(3), E-71522(2007)
29. S. K. Hanks, A. M. Quinn and T. Hunter: The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science, 241(4861), 42-52(1988)
30. S. A. Hawley, M. Davison, A. Woods, S. P. Davies, R. K. Beri, D. Carling and D. G. Hardie: Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J Biol Chem, 271(44), 27879-87(1996) (Pubitemid 26367365)
31. S. C. Stein, A. Woods, N. A. Jones, M. D. Davison and D. Carling: The regulation of AMP-activated protein kinase by phosphorylation. Biochem J, 345 Pt 3, 437-43(2000) (Pubitemid 30099070)
32. B. E. Crute, K. Seefeld, J. Gamble, B. E. Kemp and L. A. Witters: Functional domains of the alpha1 catalytic subunit of the AMP-activated protein kinase. J Biol Chem, 273(52), 35347-54(1998) (Pubitemid 29028244)
33. T. Pang, B. Xiong, J. Y. Li, B. Y. Qiu, G. Z. Jin, J. K. Shen and J. Li: Conserved alpha-helix acts as autoinhibitory sequence in AMP-activated protein kinase alpha subunits. J Biol Chem, 282(1), 495-506(2007) (Pubitemid 47076612)
34. I. Salt, J. W. Celler, S. A. Hawley, A. Prescott, A. Woods, D. Carling and D. G. Hardie: AMP-activated protein kinase: greater AMP dependence, and preferential nuclear localization, of complexes containing the alpha2 isoform. Biochem J, 334(Pt 1), 177-87(1998) (Pubitemid 28420987)
35. A. Woods, P. C. Cheung, F. C. Smith, M. D. Davison, J. Scott, R. K. Beri and D. Carling: Characterization of AMP-activated protein kinase beta and gamma subunits. Assembly of the heterotrimeric complex in vitro. J Biol Chem, 271(17), 10282-90(1996)
36. T. J. Iseli, M. Walter, B. J. van Denderen, F. Katsis, L. A. Witters, B. E. Kemp, B. J. Michell and D. Stapleton: AMP-activated protein kinase beta subunit tethers alpha and gamma subunits via its C-terminal sequence (186-270). J Biol Chem, 280(14), 13395-400(2005) (Pubitemid 40517226)
37. E. R. Hudson, D. A. Pan, J. James, J. M. Lucocq, S. A. Hawley, K. A. Green, O. Baba, T. Terashima and D. G. Hardie: A novel domain in AMP-activated protein kinase causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias. Curr Biol, 13(10), 861-6(2003) (Pubitemid 36573255)
38. G. Polekhina, A. Gupta, B. J. Michell, B. van Denderen, S. Murthy, S. C. Feil, I. G. Jennings, D. J. Campbell, L. A. Witters, M. W. Parker, B. E. Kemp and D. Stapleton: AMPK beta subunit targets metabolic stress sensing to glycogen. Curr Biol, 13(10), 867-71(2003) (Pubitemid 36573256)
39. B. E. Kemp: Bateman domains and adenosine derivatives form a binding contract. J Clin Invest, 113(2), 182-4(2004) (Pubitemid 38544202)
40. P. C. Cheung, I. P. Salt, S. P. Davies, D. G. Hardie and D. Carling: Characterization of AMP-activated protein kinase gamma-subunit isoforms and their role in AMP binding. Biochem J, 346 Pt 3, 659-69(2000) (Pubitemid 30171026)
41. J. W. Scott, S. A. Hawley, K. A. Green, M. Anis, G. Stewart, G. A. Scullion, D. G. Norman and D. G. Hardie: CBS domains form energy-sensing modules whose binding of adenosine ligands is disrupted by disease mutations. J Clin Invest, 113(2), 274-84(2004) (Pubitemid 38544212)
42. M. J. Rudolph, G. A. Amodeo, Y. Bai and L. Tong: Crystal structure of the protein kinase domain of yeast AMP-activated protein kinase Snf1. Biochem Biophys Res Commun, 337(4), 1224-8(2005) (Pubitemid 41509194)
43. G. Polekhina, A. Gupta, B. J. van Denderen, S. C. Feil, B. E. Kemp, D. Stapleton and M. W. Parker: Structural basis for glycogen recognition by AMP-activated protein kinase. Structure, 13(10), 1453-62(2005) (Pubitemid 41427585)
44. B. Xiao, R. Heath, P. Saiu, F. C. Leiper, P. Leone, C. Jing, P. A. Walker, L. Haire, J. F. Eccleston, C. T. Davis, S. R. Martin, D. Carling and S. J. Gamblin: Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature, 449(7161), 496-500(2007) (Pubitemid 47509548)
45. M. Suter, U. Riek, R. Tuerk, U. Schlattner, T. Wallimann and D. Neumann: Dissecting the role of 5'-AMP for allosteric stimulation, activation, and deactivation of AMP-activated protein kinase. J Biol Chem, 281(43), 32207-16(2006) (Pubitemid 46036775)
46. D. G. Hardie: The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci, 117(Pt 23), 5479-87(2004) (Pubitemid 40012195)
47. S. A. Hawley, J. Boudeau, J. L. Reid, K. J. Mustard, L. Udd, T. P. Makela, D. R. Alessi and D. G. Hardie: Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol, 2(4), 28(2003)
48. R. J. Shaw, M. Kosmatka, N. Bardeesy, R. L. Hurley, L. A. Witters, R. A. DePinho and L. C. Cantley: The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A, 101(10), 3329-35(2004) (Pubitemid 38338195)
49. A. Woods, S. R. Johnstone, K. Dickerson, F. C. Leiper, L. G. Fryer, D. Neumann, U. Schlattner, T. Wallimann, M. Carlson and D. Carling: LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol, 13(22), 2004-8(2003) (Pubitemid 37425212)
50. S. A. Hawley, D. A. Pan, K. J. Mustard, L. Ross, J. Bain, A. M. Edelman, B. G. Frenguelli and D. G. Hardie: Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab, 2(1), 9-19(2005) (Pubitemid 43239821)
51. A. Woods, K. Dickerson, R. Heath, S. P. Hong, M. Momcilovic, S. R. Johnstone, M. Carlson and D. Carling: Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab, 2(1), 21-33(2005) (Pubitemid 43239822)
52. R. L. Hurley, K. A. Anderson, J. M. Franzone, B. E. Kemp, A. R. Means and L. A. Witters: The Ca2+/calmodulindependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem, 280(32), 29060-6(2005) (Pubitemid 41161355)
53. F. Lan, J. M. Cacicedo, N. Ruderman and Y. Ido: SIRT1 modulation of the acetylation status, cytosolic localization and activity of LKB1; possible role in AMP-activated protein kinase activation. J Biol Chem 283(41), 27628-35(2008)
54. U. Riek, R. Scholz, P. Konarev, A. Rufer, M. Suter, A. Nazabal, P. Ringler, M. Chami, S. A. Muller, D. Neumann, M. Forstner, M. Hennig, R. Zenobi, A. Engel, D. Svergun, U. Schlattner and T. Wallimann: Structural properties of AMP-activated protein kinase: dimerization, molecular shape, and changes upon ligand binding. J Biol Chem, 283(26), 18331-43(2008)
55. M. J. Sanders, P. O. Grondin, B. D. Hegarty, M. A. Snowden and D. Carling: Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. The Biochemical journal, 403(1), 139-48(2007) (Pubitemid 46569875)
56. T. Hayashi, M. F. Hirshman, E. J. Kurth, W. W. Winder and L. J. Goodyear: Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes, 47(8), 1369-73(1998) (Pubitemid 28357021)
57. J. S. Fisher, J. Gao, D. H. Han, J. O. Holloszy and L. A. Nolte: Activation of AMP kinase enhances sensitivity of muscle glucose transport to insulin. Am J Physiol Endocrinol Metab, 282(1), E-1823(2002)
58. V. A. Narkar, M. Downes, R. T. Yu, E. Embler, Y. X. Wang, E. Banayo, M. M. Mihaylova, M. C. Nelson, Y. Zou, H. Juguilon, H. Kang, R. J. Shaw and R. M. Evans: AMPK and PPARdelta agonists are exercise mimetics. Cell, 134(3), 405-15(2008)
59. N. Fujii, M. F. Hirshman, E. M. Kane, R. C. Ho, L. E. Peter, M. M. Seifert and L. J. Goodyear: AMP-activated protein kinase alpha2 activity is not essential for contraction-and hyperosmolarity-induced glucose transport in skeletal muscle. J Biol Chem, 280(47), 39033-41(2005) (Pubitemid 41713853)
60. S. B. Jorgensen, B. Viollet, F. Andreelli, C. Frosig, J. B. Birk, P. Schjerling, S. Vaulont, E. A. Richter and J. F. Wojtaszewski: Knockout of the alpha2 but not alpha1 5'-AMP-activated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J Biol Chem, 279(2), 1070-9(2004) (Pubitemid 38082628)
61. J. Mu, E. R. Barton and M. J. Birnbaum: Selective suppression of AMP-activated protein kinase in skeletal muscle: update on 'lazy mice'. Biochem Soc Trans, 31(Pt 1), 236-41(2003) (Pubitemid 36241436)
62. N. Simard-Lefort, E. St-Amand, S. Morasse, C. H. Cote and A. Marette: The {alpha} subunit of AMPK is essential for submaximal contraction-mediated glucose transport in skeletal muscle in vitro {alpha}. Am J Physiol Endocrinol Metab (2008)
63. R. Bergeron, S. F. Previs, G. W. Cline, P. Perret, R. R. Russell, 3rd, L. H. Young and G. I. Shulman: Effect of 5-aminoimidazole-4-carboxamide-1-beta-D- ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats. Diabetes, 50(5), 1076-82(2001) (Pubitemid 32374538)
64. E. S. Buhl, N. Jessen, R. Pold, T. Ledet, A. Flyvbjerg, S. B. Pedersen, O. Pedersen, O. Schmitz and S. Lund: Long-term AICAR administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes, 51(7), 2199-206(2002) (Pubitemid 34729025)
65. M. A. Iglesias, J. M. Ye, G. Frangioudakis, A. K. Saha, E. Tomas, N. B. Ruderman, G. J. Cooney and E. W. Kraegen: AICAR administration causes an apparent enhancement of muscle and liver insulin action in insulinresistant high-fat-fed rats. Diabetes, 51(10), 2886-94(2002)
66. R. Pold, L. S. Jensen, N. Jessen, E. S. Buhl, O. Schmitz, A. Flyvbjerg, N. Fujii, L. J. Goodyear, C. F. Gotfredsen, C. L. Brand and S. Lund: Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes, 54(4), 928-34(2005) (Pubitemid 40446305)
67. X. M. Song, M. Fiedler, D. Galuska, J. W. Ryder, M. Fernstrom, A. V. Chibalin, H. Wallberg-Henriksson and J. R. Zierath: 5-Aminoimidazole-4- carboxamide ribonucleoside treatment improves glucose homeostasis in insulin-resistant diabetic (ob/ob) mice. Diabetologia, 45(1), 56-65(2002) (Pubitemid 34118543)
68. N. Fujii, R. C. Ho, Y. Manabe, N. Jessen, T. Toyoda, W. L. Holland, S. A. Summers, M. F. Hirshman and L. J. Goodyear: Ablation of AMP-activated Protein Kinase {alpha}2 Activity Exacerbates Insulin Resistance Induced by High-fat Feeding of Mice. Diabetes (2008)
69. J. L. Smith, P. B. Patil and J. S. Fisher: AICAR and hyperosmotic stress increase insulin-stimulated glucose transport. J Appl Physiol, 99(3), 877-83(2005) (Pubitemid 41214497)
70. B. F. Holmes, E. J. Kurth-Kraczek and W. W. Winder: Chronic activation of 5'-AMP-activated protein kinase increases GLUT-4, hexokinase, and glycogen in muscle. J Appl Physiol, 87(5), 1990-5(1999)
71. R. Bergeron, J. M. Ren, K. S. Cadman, I. K. Moore, P. Perret, M. Pypaert, L. H. Young, C. F. Semenkovich and G. I. Shulman: Chronic activation of AMP kinase results in NRF-1 activation and mitochondrial biogenesis. Am J Physiol Endocrinol Metab, 281(6), E-13406(2001)
72. W. W. Winder, B. F. Holmes, D. S. Rubink, E. B. Jensen, M. Chen and J. O. Holloszy: Activation of AMP-activated protein kinase increases mitochondrial enzymes in skeletal muscle. J Appl Physiol, 88(6), 2219-26(2000) (Pubitemid 30453931)
73. H. Zong, J. M. Ren, L. H. Young, M. Pypaert, J. Mu, M. J. Birnbaum and G. I. Shulman: AMP kinase is required for mitochondrial biogenesis in skeletal muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A, 99(25), 15983-7(2002) (Pubitemid 35462735)
74. S. Jager, C. Handschin, J. St-Pierre and B. M. Spiegelman: AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A, 104(29), 12017-22(2007) (Pubitemid 47185622)
75. B. F. Holmes, D. B. Lang, M. J. Birnbaum, J. Mu and G. L. Dohm: AMP kinase is not required for the GLUT4 response to exercise and denervation in skeletal muscle. Am J Physiol Endocrinol Metab, 287(4), E-73943(2004)
76. S. B. Jorgensen, J. F. Wojtaszewski, B. Viollet, F. Andreelli, J. B. Birk, Y. Hellsten, P. Schjerling, S. Vaulont, P. D. Neufer, E. A. Richter and H. Pilegaard: Effects of alpha-AMPK knockout on exercise-induced gene activation in mouse skeletal muscle. Faseb J, 19(9), 1146-8(2005) (Pubitemid 40946446)
77. K. S. Rockl, M. F. Hirshman, J. Brandauer, N. Fujii, L. A. Witters and L. J. Goodyear: skeletal muscle adaptation to exercise training: AMP-activated protein kinase mediates muscle fiber type shift. Diabetes, 56(8), 2062-9(2007) (Pubitemid 47195818)
78. M. Bluher, J. W. Bullen, Jr., J. H. Lee, S. Kralisch, M. Fasshauer, N. Kloting, J. Niebauer, M. R. Schon, C. J. Williams and C. S. Mantzoros: Circulating adiponectin and expression of adiponectin receptors in human skeletal muscle: associations with metabolic parameters and insulin resistance and regulation by physical training. J Clin Endocrinol Metab, 91(6), 2310-6(2006) (Pubitemid 43855022)
79. K. Hojlund, K. J. Mustard, P. Staehr, D. G. Hardie, H. Beck-Nielsen, E. A. Richter and J. F. Wojtaszewski: AMPK activity and isoform protein expression are similar in muscle of obese subjects with and without type 2 diabetes. Am J Physiol Endocrinol Metab, 286(2), E-23944(2004)
80. N. Musi, M. F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, O. Rooyackers, G. Zhou, J. M. Williamson, O. Ljunqvist, S. Efendic, D. E. Moller, A. Thorell and L. J. Goodyear: Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes, 51(7), 2074-81(2002) (Pubitemid 34729010)
81. L. Bertrand, A. Ginion, C. Beauloye, A. D. Hebert, B. Guigas, L. Hue and J. L. Vanoverschelde: AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol, 291(1), H-23950(2006)
82. E. P. Weiss, S. B. Racette, D. T. Villareal, L. Fontana, K. Steger-May, K. B. Schechtman, S. Klein and J. O. Holloszy: Improvements in glucose tolerance and insulin action induced by increasing energy expenditure or decreasing energy intake: a randomized controlled trial. Am J Clin Nutr, 84(5), 1033-42(2006) (Pubitemid 44730373)
83. D. E. Larson-Meyer, L. K. Heilbronn, L. M. Redman, B. R. Newcomer, M. I. Frisard, S. Anton, S. R. Smith, A. Alfonso and E. Ravussin: Effect of calorie restriction with or without exercise on insulin sensitivity, beta-cell function, fat cell size, and ectopic lipid in overweight subjects. Diabetes Care, 29(6), 1337-44(2006) (Pubitemid 44125932)
84. I. M. Jazet, G. Schaart, A. Gastaldelli, E. Ferrannini, M. K. Hesselink, P. Schrauwen, J. A. Romijn, J. A. Maassen, H. Pijl, D. M. Ouwens and A. E. Meinders: Loss of 50% of excess weight using a very low energy diet improves insulin-stimulated glucose disposal and skeletal muscle insulin signalling in obese insulin-treated type 2 diabetic patients. Diabetologia, 51(2), 309-19(2008)
85. S. Hammer, M. Snel, H. J. Lamb, I. M. Jazet, R. W. van der Meer, H. Pijl, E. A. Meinders, J. A. Romijn, A. de Roos and J. W. Smit: Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol, 52(12), 1006-12(2008)
86. K. T. Howitz, K. J. Bitterman, H. Y. Cohen, D. W. Lamming, S. Lavu, J. G. Wood, R. E. Zipkin, P. Chung, A. Kisielewski, L. L. Zhang, B. Scherer and D. A. Sinclair: Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature, 425(6954), 191-6(2003) (Pubitemid 37150899)
87. J. A. Baur, K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin, A. Kalra, V. V. Prabhu, J. S. Allard, G. Lopez-Lluch, K. Lewis, P. J. Pistell, S. Poosala, K. G. Becker, O. Boss, D. Gwinn, M. Wang, S. Ramaswamy, K. W. Fishbein, R. G. Spencer, E. G. Lakatta, D. le Couteur, R. J. Shaw, P. Navas, P. Puigserver, D. K. Ingram, R. de Cabo and D. A. Sinclair: Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 444(7117), 337-42(2006) (Pubitemid 44764104)
88. M. Zang, S. Xu, K. A. Maitland-Toolan, A. Zuccollo, X. Hou, B. Jiang, M. Wierzbicki, T. J. Verbeuren and R. A. Cohen: Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes, 55(8), 2180-91(2006) (Pubitemid 44743614)
89. M. Lagouge, C. Argmann, Z. Gerhart-Hines, H. Meziane, C. Lerin, F. Daussin, N. Messadeq, J. Milne, P. Lambert, P. Elliott, B. Geny, M. Laakso, P. Puigserver and J. Auwerx: Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell, 127(6), 1109-22(2006) (Pubitemid 44894520)
90. J. C. Milne, P. D. Lambert, S. Schenk, D. P. Carney, J. J. Smith, D. J. Gagne, L. Jin, O. Boss, R. B. Perni, C. B. Vu, J. E. Bemis, R. Xie, J. S. Disch, P. Y. Ng, J. J. Nunes, A. V. Lynch, H. Yang, H. Galonek, K. Israelian, W. Choy, A. Iffland, S. Lavu, O. Medvedik, D. A. Sinclair, J. M. Olefsky, M. R. Jirousek, P. J. Elliott and C. H. Westphal: Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature, 450(7170), 712-6(2007) (Pubitemid 350207685)
91. C. Sun, F. Zhang, X. Ge, T. Yan, X. Chen, X. Shi and Q. Zhai: SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab, 6(4), 307-19(2007) (Pubitemid 47468091)
92. A. S. Banks, N. Kon, C. Knight, M. Matsumoto, R. Gutierrez-Juarez, L. Rossetti, W. Gu and D. Accili: SirT1 gain of function increases energy efficiency and prevents diabetes in mice. Cell Metab, 8(4), 333-41(2008)
93. K. A. Moynihan, A. A. Grimm, M. M. Plueger, E. Bernal-Mizrachi, E. Ford, C. Cras-Meneur, M. A. Permutt and S. Imai: Increased dosage of mammalian Sir2 in pancreatic beta cells enhances glucose-stimulated insulin secretion in mice. Cell Metab, 2(2), 105-17(2005)
94. L. Bordone, M. C. Motta, F. Picard, A. Robinson, U. S. Jhala, J. Apfeld, T. McDonagh, M. Lemieux, M. McBurney, A. Szilvasi, E. J. Easlon, S. J. Lin and L. Guarente: Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol, 4(2), e31(2006)
95. F. Picard, M. Kurtev, N. Chung, A. Topark-Ngarm, T. Senawong, R. Machado de Oliveira, M. Leid, M. W. McBurney and L. Guarente: Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature, 429(6993), 771-6(2004) (Pubitemid 38833129)
96. J. A. Baur, K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin, A. Kalra, V. V. Prabhu, J. S. Allard, G. Lopez-Lluch, K. Lewis, P. J. Pistell, S. Poosala, K. G. Becker, O. Boss, D. Gwinn, M. Wang, S. Ramaswamy, K. W. Fishbein, R. G. Spencer, E. G. Lakatta, D. le Couteur, R. J. Shaw, P. Navas, P. Puigserver, D. K. Ingram, R. de Cabo and D. A. Sinclair: Resveratrol improves health and survival of mice on a highcalorie diet. Nature, 444(7117), 337-42(2006) (Pubitemid 44764104)
97. Q. F. Collins, H. Y. Liu, J. Pi, Z. Liu, M. J. Quon and W. Cao: Epigallocatechin-3-gallate (EGCG), a green tea polyphenol, suppresses hepatic gluconeogenesis through 5'-AMP-activated protein kinase. J Biol Chem, 282(41), 30143-9(2007) (Pubitemid 350035266)
98. X. Hou, S. Xu, K. A. Maitland-Toolan, K. Sato, B. Jiang, Y. Ido, F. Lan, K. Walsh, M. Wierzbicki, T. J. Verbeuren, R. A. Cohen and M. Zang: SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem, 283(29), 20015-26(2008)
99. B. Dasgupta and J. Milbrandt: Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci U S A, 104(17), 7217-22(2007) (Pubitemid 47186035)
100. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, J. Fenyk-Melody, M. Wu, J. Ventre, T. Doebber, N. Fujii, N. Musi, M. F. Hirshman, L. J. Goodyear and D. E. Moller: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 108(8), 1167-74(2001) (Pubitemid 32995375)
101. R. J. Shaw, K. A. Lamia, D. Vasquez, S. H. Koo, N. Bardeesy, R. A. Depinho, M. Montminy and L. C. Cantley: The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science, 310(5754), 1642-6(2005) (Pubitemid 41780780)
102. M. Foretz, N. Ancellin, F. Andreelli, Y. Saintillan, P. Grondin, A. Kahn, B. Thorens, S. Vaulont and B. Viollet: Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes, 54(5), 1331-9(2005) (Pubitemid 40586661)
103. A. Y. Viana, H. Sakoda, M. Anai, M. Fujishiro, H. Ono, A. Kushiyama, Y. Fukushima, Y. Sato, Y. Oshida, Y. Uchijima, H. Kurihara and T. Asano: Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Res Clin Pract, 73(2), 135-42(2006) (Pubitemid 43928157)
104. P. A. Lochhead, I. P. Salt, K. S. Walker, D. G. Hardie and C. Sutherland: 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes, 49(6), 896-903(2000) (Pubitemid 30349410)
105. S. H. Koo, L. Flechner, L. Qi, X. Zhang, R. A. Screaton, S. Jeffries, S. Hedrick, W. Xu, F. Boussouar, P. Brindle, H. Takemori and M. Montminy: The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature, 437(7062), 1109-11(2005)
106. R. R. Banerjee, S. M. Rangwala, J. S. Shapiro, A. S. Rich, B. Rhoades, Y. Qi, J. Wang, M. W. Rajala, A. Pocai, P. E. Scherer, C. M. Steppan, R. S. Ahima, S. Obici, L. Rossetti and M. A. Lazar: Regulation of fasted blood glucose by resistin. Science, 303(5661), 1195-8(2004) (Pubitemid 38233585)
107. T. Yamauchi, J. Kamon, Y. Minokoshi, Y. Ito, H. Waki, S. Uchida, S. Yamashita, M. Noda, S. Kita, K. Ueki, K. Eto, Y. Akanuma, P. Froguel, F. Foufelle, P. Ferre, D. Carling, S. Kimura, R. Nagai, B. B. Kahn and T. Kadowaki: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med, 8(11), 1288-95(2002) (Pubitemid 35373562)
108. F. Andreelli, M. Foretz, C. Knauf, P. D. Cani, C. Perrin, M. A. Iglesias, B. Pillot, A. Bado, F. Tronche, G. Mithieux, S. Vaulont, R. Burcelin and B. Viollet: Liver adenosine monophosphate-activated kinase-alpha2 catalytic subunit is a key target for the control of hepatic glucose production by adiponectin and leptin but not insulin. Endocrinology, 147(5), 2432-41(2006)
109. H. A. Koistinen, D. Galuska, A. V. Chibalin, J. Yang, J. R. Zierath, G. D. Holman and H. Wallberg-Henriksson: 5-amino-imidazole carboxamide riboside increases glucose transport and cell-surface GLUT4 content in skeletal muscle from subjects with type 2 diabetes. Diabetes, 52(5), 1066-72(2003) (Pubitemid 36523338)
110. K. Sakamoto and G. D. Holman: Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab, 295(1), E-2937(2008)
111. E. B. Taylor, D. An, H. F. Kramer, H. Yu, N. L. Fujii, K. S. Roeckl, N. Bowles, M. F. Hirshman, J. Xie, E. P. Feener and L. J. Goodyear: Discovery of TBC1D1 as an insulin-, AICAR-, and contraction-stimulated signaling nexus in mouse skeletal muscle. J Biol Chem, 283(15), 9787-96(2008)
112. H. C. Dreyer, M. J. Drummond, E. L. Glynn, S. Fujita, D. L. Chinkes, E. Volpi and B. B. Rasmussen: Resistance exercise increases human skeletal muscle AS160/TBC1D4 phosphorylation in association with enhanced leg glucose uptake during post-exercise recovery. J Appl Physiol (2008)
113. A. Sriwijitkamol, D. K. Coletta, E. Wajcberg, G. B. Balbontin, S. M. Reyna, J. Barrientes, P. A. Eagan, C. P. Jenkinson, E. Cersosimo, R. A. DeFronzo, K. Sakamoto and N. Musi: Effect of acute exercise on AMPK signaling in skeletal muscle of subjects with type 2 diabetes: a timecourse and dose-response study. Diabetes, 56(3), 836-48(2007) (Pubitemid 46348486)
114. L. Storlien, N. D. Oakes and D. E. Kelley: Metabolic flexibility. Proc Nutr Soc, 63(2), 363-8(2004) (Pubitemid 38787491)
115. K. F. Petersen, E. A. Oral, S. Dufour, D. Befroy, C. Ariyan, C. Yu, G. W. Cline, A. M. DePaoli, S. I. Taylor, P. Gorden and G. I. Shulman: Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest, 109(10), 1345-50(2002) (Pubitemid 34546899)
116. S. Kamohara, R. Burcelin, J. L. Halaas, J. M. Friedman and M. J. Charron: Acute stimulation of glucose metabolism in mice by leptin treatment. Nature, 389(6649), 374-7(1997) (Pubitemid 27415217)
117. Y. Minokoshi, M. S. Haque and T. Shimazu: Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes, 48(2), 287-91(1999) (Pubitemid 29061100)
118. Y. Minokoshi, Y. B. Kim, O. D. Peroni, L. G. Fryer, C. Muller, D. Carling and B. B. Kahn: Leptin stimulates fattyacid oxidation by activating AMP-activated protein kinase. Nature, 415(6869), 339-43(2002) (Pubitemid 34087557)
119. C. R. Bruce, V. A. Mertz, G. J. Heigenhauser and D. J. Dyck: The stimulatory effect of globular adiponectin on insulin-stimulated glucose uptake and fatty acid oxidation is impaired in skeletal muscle from obese subjects. Diabetes, 54(11), 3154-60(2005) (Pubitemid 43334369)
120. M. A. Febbraio and B. K. Pedersen: Contraction-induced myokine production and release: is skeletal muscle an endocrine organ? Exerc Sport Sci Rev, 33(3), 114-9(2005) (Pubitemid 40994563)
121. S. Glund, A. Deshmukh, Y. C. Long, T. Moller, H. A. Koistinen, K. Caidahl, J. R. Zierath and A. Krook: Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes, 56(6), 1630-7(2007) (Pubitemid 46842596)
122. I. Nieto-Vazquez, S. Fernandez-Veledo, C. de Alvaro and M. Lorenzo: Dual Role of Interleukin-6 in Regulating Insulin Sensitivity in Murine skeletal Muscle. Diabetes (2008)
123. S. Glund, J. T. Treebak, Y. C. Long, R. Barres, B. Viollet, J. F. Wojtaszewski and J. R. Zierath: Role of AMPK in IL-6 release from isolated mouse skeletal muscle. Endocrinology (2008)
124. I. Leclerc, C. Lenzner, L. Gourdon, S. Vaulont, A. Kahn and B. Viollet: Hepatocyte nuclear factor-4alpha involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase. Diabetes, 50(7), 1515-21(2001) (Pubitemid 33639590)
125. A. Woods, D. Azzout-Marniche, M. Foretz, S. C. Stein, P. Lemarchand, P. Ferre, F. Foufelle and D. Carling: Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol, 20(18), 6704-11(2000)
126. M. Foretz, D. Carling, C. Guichard, P. Ferre and F. Foufelle: AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J Biol Chem, 273(24), 14767-71(1998) (Pubitemid 28272762)
127. I. Leclerc, A. Kahn and B. Doiron: The 5'-AMP-activated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex. FEBS Lett, 431(2), 180-4(1998) (Pubitemid 28334212)
128. M. M. Assifi, G. Suchankova, S. Constant, M. Prentki, A. K. Saha and N. B. Ruderman: AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am J Physiol Endocrinol Metab, 289(5), E-794800(2005)
129. G. F. Merrill, E. J. Kurth, D. G. Hardie and W. W. Winder: AICA riboside increases AMP-activated protein kinase, fatty acid oxidation, and glucose uptake in rat muscle. Am J Physiol, 273(6 Pt 1), E1107-12(1997)
130. W. J. Lee, M. Kim, H. S. Park, H. S. Kim, M. J. Jeon, K. S. Oh, E. H. Koh, J. C. Won, M. S. Kim, G. T. Oh, M. Yoon, K. U. Lee and J. Y. Park: AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARalpha and PGC-1. Biochem Biophys Res Commun, 340(1), 291-5(2006) (Pubitemid 41827679)
131. B. R. Barnes, S. Marklund, T. L. Steiler, M. Walter, G. Hjalm, V. Amarger, M. Mahlapuu, Y. Leng, C. Johansson, D. Galuska, K. Lindgren, M. Abrink, D. Stapleton, J. R. Zierath and L. Andersson: The 5'-AMP-activated protein kinase gamma3 isoform has a key role in carbohydrate and lipid metabolism in glycolytic skeletal muscle. J Biol Chem, 279(37), 38441-7(2004) (Pubitemid 39295995)
132. N. L. Dzamko, J. D. Schertzer, J. Ryall, R. Steel, S. L. Macaulay, S. Wee, Z. P. Chen, B. J. Michell, J. S. Oakhill, M. J. Watt, S. B. Jorgensen, G. S. Lynch, B. E. Kemp and G. R. Steinberg: AMPK independent pathways regulate skeletal muscle fatty acid oxidation. J Physiol (2008)
133. A. C. Smith, C. R. Bruce and D. J. Dyck: AMP kinase activation with AICAR further increases fatty acid oxidation and blunts triacylglycerol hydrolysis in contracting rat soleus muscle. J Physiol, 565(Pt 2), 547-53(2005) (Pubitemid 40872481)
134. J. F. Wojtaszewski, M. Mourtzakis, T. Hillig, B. Saltin and H. Pilegaard: Dissociation of AMPK activity and ACCbeta phosphorylation in human muscle during prolonged exercise. Biochem Biophys Res Commun, 298(3), 309-16(2002) (Pubitemid 35333706)
135. C. Roepstorff, N. Halberg, T. Hillig, A. K. Saha, N. B. Ruderman, J. F. Wojtaszewski, E. A. Richter and B. Kiens: Malonyl-CoA and carnitine in regulation of fat oxidation in human skeletal muscle during exercise. Am J Physiol Endocrinol Metab, 288(1), E-13342(2005)
136. H. Z. Lin, S. Q. Yang, C. Chuckaree, F. Kuhajda, G. Ronnet and A. M. Diehl: Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med, 6(9), 998-1003(2000)
137. A. Xu, Y. Wang, H. Keshaw, L. Y. Xu, K. S. Lam and G. J. Cooper: The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest, 112(1), 91-100(2003) (Pubitemid 38056380)
138. T. Yamauchi, J. Kamon, H. Waki, Y. Terauchi, N. Kubota, K. Hara, Y. Mori, T. Ide, K. Murakami, N. Tsuboyama-Kasaoka, O. Ezaki, Y. Akanuma, O. Gavrilova, C. Vinson, M. L. Reitman, H. Kagechika, K. Shudo, M. Yoda, Y. Nakano, K. Tobe, R. Nagai, S. Kimura, M. Tomita, P. Froguel and T. Kadowaki: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med, 7(8), 941-6(2001) (Pubitemid 32756432)
139. B. Cool, B. Zinker, W. Chiou, L. Kifle, N. Cao, M. Perham, R. Dickinson, A. Adler, G. Gagne, R. Iyengar, G. Zhao, K. Marsh, P. Kym, P. Jung, H. S. Camp and E. Frevert: Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab, 3(6), 403-16(2006) (Pubitemid 43811782)
140. J. T. Rodgers and P. Puigserver: Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci U S A, 104(31), 12861-6(2007) (Pubitemid 47255245)
141. B. Guigas, N. Taleux, M. Foretz, D. Detaille, F. Andreelli, B. Viollet and L. Hue: AMP-activated protein kinase-independent inhibition of hepatic mitochondrial oxidative phosphorylation by AICA riboside. Biochem J, 404(3), 499-507(2007) (Pubitemid 46953924)
142. H. Boon, M. Bosselaar, S. F. Praet, E. E. Blaak, W. H. Saris, A. J. Wagenmakers, S. L. McGee, C. J. Tack, P. Smits, M. Hargreaves and L. J. van Loon: Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients. Diabetologia, 51(10), 1893-900(2008)
143. S. E. Kahn: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia, 46(1), 3-19(2003) (Pubitemid 36237741)
144. U. K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U. K. Prospective Diabetes Study Group. Diabetes, 44(11), 1249-58(1995)
145. M. Prentki, E. Joly, W. El-Assaad and R. Roduit: Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes. Diabetes, 51 Suppl 3, S405-13 (2002) (Pubitemid 35403424)
146. W. El-Assaad, J. Buteau, M. L. Peyot, C. Nolan, R. Roduit, S. Hardy, E. Joly, G. Dbaibo, L. Rosenberg and M. Prentki: Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology, 144(9), 4154-63(2003) (Pubitemid 37088771)
147. M. Higa, Y. T. Zhou, M. Ravazzola, D. Baetens, L. Orci and R. H. Unger: Troglitazone prevents mitochondrial alterations, beta cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci U S A, 96(20), 11513-8(1999) (Pubitemid 29487412)
148. R. Lupi, S. del Guerra, V. Fierabracci, L. Marselli, M. Novelli, G. Patane, U. Boggi, F. Mosca, S. Piro, S. del Prato and P. Marchetti: Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes, 51 Suppl 1, S134-7 (2002) (Pubitemid 34761508)
149. K. Eto, T. Yamashita, J. Matsui, Y. Terauchi, M. Noda and T. Kadowaki: Genetic manipulations of fatty acid metabolism in beta-cells are associated with dysregulated insulin secretion. Diabetes, 51 Suppl 3, S414-20 (2002) (Pubitemid 35403425)
150. B. A. Kefas, H. Heimberg, S. Vaulont, D. Meisse, L. Hue, D. Pipeleers and M. Van de Casteele: AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase. Diabetologia, 46(2), 250-4(2003) (Pubitemid 36343889)
151. B. A. Kefas, Y. Cai, Z. Ling, H. Heimberg, L. Hue, D. Pipeleers and M. Van de Casteele: AMP-activated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J Mol Endocrinol, 30(2), 151-61(2003) (Pubitemid 36592509)
152. A. Riboulet-Chavey, F. Diraison, L. K. Siew, F. S. Wong and G. A. Rutter: Inhibition of AMP-activated protein kinase protects pancreatic beta-cells from cytokinemediated apoptosis and CD8+ T-cell-induced cytotoxicity. Diabetes, 57(2), 415-23(2008)
153. W. H. Kim, J. W. Lee, Y. H. Suh, H. J. Lee, S. H. Lee, Y. K. Oh, B. Gao and M. H. Jung: AICAR potentiates ROS production induced by chronic high glucose: roles of AMPK in pancreatic beta-cell apoptosis. Cell Signal, 19(4), 791-805(2007) (Pubitemid 46275369)
154. P. Marchetti, S. del Guerra, L. Marselli, R. Lupi, M. Masini, M. Pollera, M. Bugliani, U. Boggi, F. Vistoli, F. Mosca and S. del Prato: Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab, 89(11), 5535-41(2004) (Pubitemid 39518437)
155. S. K. Richards, L. E. Parton, I. Leclerc, G. A. Rutter and R. M. Smith: Over-expression of AMP-activated protein kinase impairs pancreatic {beta}-cell function in vivo. J Endocrinol, 187(2), 225-35(2005) (Pubitemid 41685182)
156. I. Leclerc, W. W. Woltersdorf, G. da Silva Xavier, R. L. Rowe, S. E. Cross, G. S. Korbutt, R. V. Rajotte, R. Smith and G. A. Rutter: Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion. Am J Physiol Endocrinol Metab, 286(6), E-102331(2004)
157. G. da Silva Xavier, I. Leclerc, A. Varadi, T. Tsuboi, S. K. Moule and G. A. Rutter: Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. Biochem J, 371(Pt 3), 761-74(2003) (Pubitemid 36578875)
158. I. P. Salt, G. Johnson, S. J. Ashcroft and D. G. Hardie: AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J, 335(Pt 3), 533-9(1998) (Pubitemid 28515405)
159. X. Wang, L. Zhou, L. Shao, L. Qian, X. Fu, G. Li, T. Luo, Y. Gu, F. Li, J. Li, S. Zheng and M. Luo: Troglitazone acutely activates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Life Sci, 81(2), 160-5(2007) (Pubitemid 46929110)
160. L. Zhou, X. Wang, L. Shao, Y. Yang, W. Shang, G. Yuan, B. Jiang, F. Li, J. Tang, H. Jing and M. Chen: Berberine acutely inhibits insulin secretion from beta-cells through 3', 5'-cyclic adenosine 5'-monophosphate signaling pathway. Endocrinology, 149(9), 4510-8(2008)
161. T. Tsuboi, G. da Silva Xavier, I. Leclerc and G. A. Rutter: 5'-AMP-activated protein kinase controls insulincontaining secretory vesicle dynamics. J Biol Chem, 278(52), 52042-51(2003) (Pubitemid 38035789)
162. R. D. Carr, C. L. Brand, T. B. Bodvarsdottir, J. B. Hansen and J. Sturis: NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat. Diabetes, 52(10), 2513-8(2003) (Pubitemid 37210539)
163. A. E. Butler, J. Janson, S. Bonner-Weir, R. Ritzel, R. A. Rizza and P. C. Butler: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes, 52(1), 102-10(2003) (Pubitemid 36042113)
164. A. Pick, J. Clark, C. Kubstrup, M. Levisetti, W. Pugh, S. Bonner-Weir and K. S. Polonsky: Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes, 47(3), 358-64(1998) (Pubitemid 28104196)
165. C. E. Murry, R. B. Jennings and K. A. Reimer: Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation, 74(5), 1124-36(1986) (Pubitemid 17174962)
166. Y. Nishino, T. Miura, T. Miki, J. Sakamoto, Y. Nakamura, Y. Ikeda, H. Kobayashi and K. Shimamoto: Ischemic preconditioning activates AMPK in a PKC-dependent manner and induces GLUT4 up-regulation in the late phase of cardioprotection. Cardiovascular research, 61(3), 610-9(2004) (Pubitemid 38210166)
167. R. Shibata, K. Sato, D. R. Pimentel, Y. Takemura, S. Kihara, K. Ohashi, T. Funahashi, N. Ouchi and K. Walsh: Adiponectin protects against myocardial ischemiareperfusion injury through AMPK-and COX-2-dependent mechanisms. Nat Med, 11(10), 1096-103(2005) (Pubitemid 41486832)
168. R. Shibata, N. Ouchi, M. Ito, S. Kihara, I. Shiojima, D. R. Pimentel, M. Kumada, K. Sato, S. Schiekofer, K. Ohashi, T. Funahashi, W. S. Colucci and K. Walsh: Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat Med, 10(12), 1384-9(2004) (Pubitemid 40022722)
169. D. Fujioka, K. Kawabata, Y. Saito, T. Kobayashi, T. Nakamura, Y. Kodama, H. Takano, J. E. Obata, Y. Kitta, K. Umetani and K. Kugiyama: Role of adiponectin receptors in endothelin-induced cellular hypertrophy in cultured cardiomyocytes and their expression in infarcted heart. Am J Physiol Heart Circ Physiol, 290(6), H-240916(2006)
170. J. B. Majithiya and R. Balaraman: Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats. Life Sci, 78(22), 2615-24(2006)
171. L. J. Rubin, L. Magliola, X. Feng, A. W. Jones and C. C. Hale: Metabolic activation of AMP kinase in vascular smooth muscle. J Appl Physiol, 98(1), 296-306(2005) (Pubitemid 40041260)
172. A. M. Evans, K. J. Mustard, C. N. Wyatt, C. Peers, M. Dipp, P. Kumar, N. P. Kinnear and D. G. Hardie: Does AMP-activated protein kinase couple inhibition of mitochondrial oxidative phosphorylation by hypoxia to calcium signaling in O2-sensing cells? J Biol Chem, 280(50), 41504-11(2005) (Pubitemid 41832211)
173. R. Shibata, N. Ouchi, S. Kihara, K. Sato, T. Funahashi and K. Walsh: Adiponectin stimulates angiogenesis in response to tissue ischemia through stimulation of ampactivated protein kinase signaling. J Biol Chem, 279(27), 28670-4(2004) (Pubitemid 38900150)
174. Y. Minokoshi, T. Alquier, N. Furukawa, Y. B. Kim, A. Lee, B. Xue, J. Mu, F. Foufelle, P. Ferre, M. J. Birnbaum, B. J. Stuck and B. B. Kahn: AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature, 428(6982), 569-74(2004) (Pubitemid 38480541)
175. B. Cool, B. Zinker, W. Chiou, L. Kifle, N. Cao, M. Perham, R. Dickinson, A. Adler, G. Gagne, R. Iyengar, G. Zhao, K. Marsh, P. Kym, P. Jung, H. S. Camp and E. Frevert: Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell metabolism, 3(6), 403-16(2006) (Pubitemid 43811782)
176. D. J. Cuthbertson, J. A. Babraj, K. J. Mustard, M. C. Towler, K. A. Green, H. Wackerhage, G. P. Leese, K. Baar, M. Thomason-Hughes, C. Sutherland, D. G. Hardie and M. J. Rennie: 5-aminoimidazole-4-carboxamide 1-beta-D-ribofuranoside acutely stimulates skeletal muscle 2-deoxyglucose uptake in healthy men. Diabetes, 56(8), 2078-84(2007) (Pubitemid 47195820)